An exploratory analysis of objective responses to neoadjuvant chemotherapy: results from a randomised phase III trial evaluating first-line carboplatin-paclitaxel regimens for ovarian, fallopian tube or primary peritoneal carcinoma (ICON8)

Autor: McNeish, I, Morgan, RD, Cook, AD, James, EC, Lord, R, Dark, G, Glasspool, RM, Krell, J, Parkinson, C, Poole, CJ, Hall, M, Gallardo-Rincón, D, Lockley, M, Essapen, S, Summers, J, Anand, A, Zachariah, A, Williams, S, Jones, R, Scatchard, K, Walther, A, Kim, J-W, Sundar, S, Jayson, GC, Ledermann, JA, Clamp, AR

BackgroundPlatinum-based neoadjuvant chemotherapy (NACT) followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced stage epithelial ovarian cancer. Although this therapeutic approach has been valida

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::9636d15c7a38b268fbe7c56d2b27da23
http://hdl.handle.net/10044/1/83730

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7):overall survival results of a phase 3 randomised trial

Autor: Oza, AM, Cook, AD, Pfisterer, J, Embleton, A, Ledermann, JA, Pujade-Lauraine, E, Kristensen, G, Carey, MS, Beale, P, Cervantes, A, Park-Simon, T-W, Rustin, G, Joly, F, Mirza, MR, Plante, M, Quinn, M, Poveda, A, Jayson, GC, Stark, D, Swart, AM, Farrelly, L, Kaplan, R, Parmar, MKB, Perren, TJ

Publikováno v: Oza, A M, Cook, A D, Pfisterer, J, Embleton, A, Ledermann, J A, Pujade-Lauraine, E, Kristensen, G, Carey, M S, Beale, P, Cervantes, A, Park-Simon, T-W, Rustin, G, Joly, F, Mirza, M R, Plante, M, Quinn, M S, Poveda, A, Jayson, G C, Stark, D, Swart, A M, Farrelly, L, Kaplan, R, Parmar, M K B, Perren, T J & ICON7 trial investigators 2015, ' Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7) : overall survival results of a phase 3 randomised trial ', Lancet Oncology, vol. 16, no. 8, pp. 928-936 . https://doi.org/10.1016/S1470-2045(15)00086-8

BACKGROUND: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8dee481155bef518cb7d7907f28f5f8f
https://vbn.aau.dk/da/publications/eb7eb733-cabd-47b8-b97c-4c9966777fa3

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.